Publications by authors named "Maria Jose Lechuga"

Claim this Profile
E
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
Michelle Casey, Evgeny Degtyarev, María José Lechuga, Paola Aimone, Alain Ravaud

Pharm Stat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, Russell Szmulewitz, Thomas Powles, Maria Josè Lechuga

Oncologist· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Brian I Rini, Thomas E Hutson, Robert A Figlin, Maria Josè Lechuga, Olga Valota

Clin Genitourin Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.
Masatoshi Kudo, Yoon-Koo Kang, Joong-Won Park, Shukui Qin, Yoshitaka Inaba, Maria José Lechuga

Liver Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Peter Reichardt, George D Demetri, Hans Gelderblom, Piotr Rutkowski, Seock-Ah Im, Maria Jose Lechuga

BMC Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
J Randolph Hecht, Edith P Mitchell, Takayuki Yoshino, Manfred Welslau, Xun Lin, Maria Jose Lechuga

Cancer Manag Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S Rosen, Maria José Lechuga

Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, Lisa Sengeløv, Fred Saad, Maria Jose Lechuga

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, Joong-Won Park, Masatoshi Kudo, Maria Jose Lechuga

J Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Yasushi Tsuji, Taroh Satoh, Akihito Tsuji, Kei Muro, Motoki Yoshida, Maria Jose Lechuga

Cancer Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
Takayuki Yoshino, Kentaro Yamazaki, Tetsuya Hamaguchi, Yasuhiro Shimada, Ken Kato, Maria Jose Lechuga

Anticancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Charles S Harmon, Samuel E DePrimo, Eric Raymond, Ann-Lii Cheng, Eveline Boucher, Maria José Lechuga

J Transl Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis